CLIME-CJD: A Multimodal Study

A Multimodal Retrospective Cohort Analysis of Clinical, Laboratory, Neuroimaging, Electroencephalographic, and Biomarker Characteristics in Patients With Creutzfeldt-Jakob Disease: The CLIME-CJD Study

Status

Enrolling by invitation

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07589283

Enrollment

150

Registered

2026-05-15

Start date

2022-01-01

Completion date

2031-12-01

Last updated

2026-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Creutzfeldt-Jakob Disease (CJD) | Prion Disease

Brief summary

Creutzfeldt-Jakob disease (CJD) is a rare and rapidly progressive neurological disorder. This study aims to describe and summarize the key features of CJD by looking back at medical records of patients who were diagnosed with CJD at our hospital. The researchers will collect information from routine clinical evaluations, including patients' symptoms, blood tests, cerebrospinal fluid analysis, brain imaging (such as MRI and PET), and electroencephalography (EEG). By analyzing these data together, the study hopes to provide a clearer picture of how CJD presents in routine clinical practice. This may help doctors recognize the disease more quickly in the future. No new tests or treatments will be given to patients. All data are collected from existing medical records.

Interventions

OTHERNo Interventions

No Interventions

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Inclusion criteria

* Diagnosis of definite or probable Creutzfeldt-Jakob Disease (CJD) according to the established WHO diagnostic criteria * Available medical records covering at least one of the following: clinical history, peripheral blood test results, cerebrospinal fluid (CSF) analysis findings, brain MRI reports/images, or EEG reports * Hospitalized or evaluated at the participating institution during the study period

Exclusion criteria

* Alternative diagnosis confirmed that explains all clinical features (e.g., autoimmune encephalitis, rapidly progressive dementia due to other causes) * Incomplete medical records with no relevant clinical, laboratory, imaging, or EEG data available * Patient or legal representative declined the use of medical records for research purposes (where applicable according to local regulations)

Design outcomes

Primary

Measure	Time frame	Description
Proportion of CJD Patients With Characteristic Diagnostic Findings	Baseline	The primary outcome is the proportion of patients showing characteristic abnormalities across five domains: clinical symptoms, peripheral blood markers, cerebrospinal fluid 14-3-3 protein and RT-QuIC, brain MRI (cortical ribboning or basal ganglia hyperintensity), and EEG (periodic sharp wave complexes).

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 16, 2026